BridgeBio officer reports tax share withholding on RSU vesting

BridgeBio Pharma, Inc. reported an equity transaction by its Chief Accounting Officer, Maricel Apuli.

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. reported an equity transaction by its Chief Accounting Officer, Maricel Apuli. On 12/12/2025, 2,003 shares of common stock were withheld to satisfy the officer's tax obligation arising from the vesting of 3,944 restricted stock units. The transaction price reported for the withheld shares was $75.15 per share. After this withholding, the officer beneficially owned 128,294 shares of BridgeBio Pharma common stock in direct ownership.

Insider Trade Summary

Exercise Price or Tax Liability: 2,003 shares

Exercise Price or Tax Liability 1 txn

Insider Apuli Maricel

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	2,003	$75.15	$151K

Holdings After Transaction: Common Stock — 128,294 shares (Direct)

Footnotes (1)

1. F1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,944 shares of Common Stock underlying the Reporting Person's Restricted Stock Units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share transaction did BridgeBio Pharma (BBIO) report on December 12, 2025?

The report shows that on 12/12/2025, BridgeBio Pharma's Chief Accounting Officer had 2,003 shares of common stock withheld to cover taxes related to a restricted stock unit vesting.

How many BridgeBio Pharma (BBIO) shares were withheld for taxes in this Form 4?

The filing states that 2,003 shares of BridgeBio Pharma common stock were withheld to satisfy the reporting person's tax obligation.

What RSU vesting triggered the tax withholding reported for BridgeBio Pharma (BBIO)?

The tax withholding relates to the vesting of 3,944 shares of BridgeBio Pharma common stock underlying the reporting person's restricted stock units.

How many BridgeBio Pharma (BBIO) shares does the reporting officer own after the transaction?

Following the reported transaction, the officer beneficially owned 128,294 shares of BridgeBio Pharma common stock in direct ownership.

Who is the reporting person in this BridgeBio Pharma (BBIO) Form 4 and what is their role?

The reporting person is Maricel Apuli, who is listed as an officer of BridgeBio Pharma with the title Chief Accounting Officer.

Is this BridgeBio Pharma (BBIO) Form 4 filed by one person or multiple reporting persons?

The document indicates that it is a Form filed by one reporting person, not a joint or group filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/16/2025 - 06:24 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Apuli Maricel

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		F		2,003(1)	D	$75.15	128,294	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,944 shares of Common Stock underlying the Reporting Person's Restricted Stock Units.

Remarks:

	/s/ Maricel Apuli	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.